AVS Bio

AVS Bio

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

AVS Bio operates at the intersection of biologics manufacturing and drug discovery services, with a core foundation in Specific Pathogen-Free (SPF) eggs and avian biologicals. It has expanded into a full-service provider offering custom antibody and protein engineering, preclinical testing via its UK-based CRO RoukenBio, and support for clinical-stage programs. The company serves a diverse market from global biopharma to animal health, boasting a substantial production history and a portfolio that supports products from research through clinical trials.

InflammationAutoimmunityImmuno-OncologyOncologyInfectious Disease

Technology Platform

Integrated platform centered on USDA-licensed avian biological manufacturing (SPF eggs, antigens) combined with antibody/protein engineering and a specialized immunology CRO (RoukenBio) for preclinical immune cell assay testing.

Funding History

2
Total raised:$10.5M
Series A$8M
Seed$2.5M

Opportunities

Growing demand for biologics and vaccine materials creates a stable foundation.
Expansion into high-value antibody discovery and preclinical CRO services offers significant margin and revenue growth potential by becoming an end-to-end partner for biopharma clients.

Risk Factors

Business faces operational risks related to avian flock health and biosecurity.
The competitive landscape for CRO and biologics services is intense, requiring continuous differentiation.
Successful integration of material supply with sophisticated research services across geographies is an execution challenge.

Competitive Landscape

Competes with large life science tools suppliers (e.g., Thermo Fisher, Merck KGaA) for materials and with global CROs (e.g., Charles River, Labcorp) for discovery services. Differentiation lies in its specialized avian platform, integrated offering, and niche immunology expertise through RoukenBio.